{"id":1161,"date":"2024-06-06T20:56:33","date_gmt":"2024-06-06T20:56:33","guid":{"rendered":"https:\/\/healthmedicinet.com\/review\/new-combination-therapy-shows-promise-for-bladder-cancer-patients-unresponsive-to-standard-treatment\/"},"modified":"2024-06-06T20:56:33","modified_gmt":"2024-06-06T20:56:33","slug":"new-combination-therapy-shows-promise-for-bladder-cancer-patients-unresponsive-to-standard-treatment","status":"publish","type":"post","link":"https:\/\/healthmedicinet.com\/review\/new-combination-therapy-shows-promise-for-bladder-cancer-patients-unresponsive-to-standard-treatment\/","title":{"rendered":"New combination therapy shows promise for bladder cancer patients unresponsive to standard treatment"},"content":{"rendered":"<p>In an advance that could transform bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer. Results from the phase 2 CORE-001 trial, published today in Nature Medicine, reveal a significant improvement in complete response rates and long-term disease control, offering new hope for patients with this challenging condition who face limited treatment options. The trial included patients with BCG-unresponsive carcinoma in situ of the bladder, a condition that is notoriously difficult to treat and <a class=\"read-more-link\" href=\"https:\/\/healthmedicinet.com\/new-combination-therapy-shows-promise-for-bladder-cancer-patients-unresponsive-to-standard-treatment\/\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In an advance that could transform bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer. Results from the phase 2 CORE-001 trial, published today in Nature Medicine, reveal a significant improvement in complete response rates and long-term disease control, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1161","post","type-post","status-publish","format-standard","hentry","category-health-news"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/posts\/1161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/comments?post=1161"}],"version-history":[{"count":0,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/posts\/1161\/revisions"}],"wp:attachment":[{"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/media?parent=1161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/categories?post=1161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthmedicinet.com\/review\/wp-json\/wp\/v2\/tags?post=1161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}